Jazz Pharmaceuticals plc Revenues
Jazz Pharmaceuticals plc (JAZZ) reported Revenues of $476.46 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2019-02-26
- Jazz Pharmaceuticals plc revenues for the quarter ending 2018-12-31 was $476.46M, a 9.18% increase year-over-year.
- Jazz Pharmaceuticals plc revenues for the quarter ending 2018-09-30 was $469.37M, a 13.97% increase year-over-year.
- Jazz Pharmaceuticals plc revenues for the quarter ending 2018-06-30 was $500.48M, a 26.90% increase year-over-year.
- Jazz Pharmaceuticals plc revenues for the quarter ending 2018-03-31 was $444.61M, a 18.23% increase year-over-year.
- Jazz Pharmaceuticals plc revenues for fiscal 2017 was $1.62B, a 8.79% increase from fiscal 2016.
- Jazz Pharmaceuticals plc revenues for fiscal 2016 was $1.49B, a 12.32% increase from fiscal 2015.
- Jazz Pharmaceuticals plc revenues for fiscal 2015 was $1.32B, a 12.95% increase from fiscal 2014.
- Jazz Pharmaceuticals plc revenues for fiscal 2014 was $1.17B, a 34.44% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $476.46M 10-K · filed 2019-02-26 | $945.83M derived: sum of 2 quarters · filed 2019-02-26 | $1.45B derived: sum of 3 quarters · filed 2019-02-26 | $1.89B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2018-09-30 | $469.37M 10-K · filed 2019-02-26 | $969.85M derived: sum of 2 quarters · filed 2019-02-26 | $1.41B derived: sum of 3 quarters · filed 2019-02-26 | $1.85B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2018-06-30 | $500.48M 10-K · filed 2019-02-26 | $945.09M derived: sum of 2 quarters · filed 2019-02-26 | $1.38B derived: sum of 3 quarters · filed 2019-02-26 | $1.79B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2018-03-31 | $444.61M 10-K · filed 2019-02-26 | $881.01M derived: sum of 2 quarters · filed 2019-02-26 | $1.29B derived: sum of 3 quarters · filed 2019-02-26 | $1.69B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-12-31 | $436.40M 10-K · filed 2019-02-26 | $848.25M derived: sum of 2 quarters · filed 2019-02-26 | $1.24B derived: sum of 3 quarters · filed 2019-02-26 | $1.62B 10-K · filed 2018-02-27 | ||
| 2017-09-30 | $411.86M 10-K · filed 2019-02-26 | $806.24M derived: sum of 2 quarters · filed 2019-02-26 | $1.18B 10-Q · filed 2017-11-07 | $1.58B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $394.39M 10-K · filed 2019-02-26 | $770.44M 10-Q · filed 2017-08-08 | $1.17B derived: sum of 3 quarters · filed 2019-02-26 | $1.54B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $376.05M 10-K · filed 2019-02-26 | $772.67M derived: sum of 2 quarters · filed 2019-02-26 | $1.15B derived: sum of 3 quarters · filed 2019-02-26 | $1.53B derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $396.62M 10-K · filed 2018-02-27 | $770.80M derived: sum of 2 quarters · filed 2018-02-27 | $1.15B derived: sum of 3 quarters · filed 2018-02-27 | $1.49B 10-K · filed 2018-02-27 | ||
| 2016-09-30 | $374.18M 10-K · filed 2018-02-27 | $755.34M derived: sum of 2 quarters · filed 2018-02-27 | $1.09B 10-Q · filed 2017-11-07 | $1.43B derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $381.16M 10-K · filed 2018-02-27 | $717.17M 10-Q · filed 2017-08-08 | $1.06B derived: sum of 3 quarters · filed 2018-02-27 | $1.40B derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $336.01M 10-K · filed 2018-02-27 | $676.89M derived: sum of 2 quarters · filed 2018-02-27 | $1.02B derived: sum of 3 quarters · filed 2018-02-27 | $1.35B derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $340.88M 10-K · filed 2017-02-28 | $681.75M derived: sum of 2 quarters · filed 2017-02-28 | $1.02B derived: sum of 3 quarters · filed 2017-02-28 | $1.32B 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $340.87M 10-K · filed 2017-02-28 | $674.62M derived: sum of 2 quarters · filed 2017-02-28 | $983.92M 10-Q · filed 2016-11-08 | $1.31B derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $333.75M 10-K · filed 2017-02-28 | $643.05M 10-Q · filed 2016-08-09 | $971.19M derived: sum of 3 quarters · filed 2017-02-28 | $1.28B derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $309.30M 10-K · filed 2017-02-28 | $637.45M derived: sum of 2 quarters · filed 2017-02-28 | $944.03M derived: sum of 3 quarters · filed 2017-02-28 | $1.24B derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $328.14M 10-K · filed 2016-02-23 | $634.73M derived: sum of 2 quarters · filed 2016-02-23 | $925.96M derived: sum of 3 quarters · filed 2016-02-23 | $1.17B 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $306.58M 10-K · filed 2016-02-23 | $597.81M derived: sum of 2 quarters · filed 2016-02-23 | $844.73M 10-Q · filed 2015-11-09 | $1.08B derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-06-30 | $291.23M 10-K · filed 2016-02-23 | $538.15M 10-Q · filed 2015-08-05 | $773.92M derived: sum of 3 quarters · filed 2016-02-23 | $1.01B derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-03-31 | $246.92M 10-K · filed 2016-02-23 | $482.69M derived: sum of 2 quarters · filed 2016-02-23 | $714.85M derived: sum of 3 quarters · filed 2016-02-23 | $923.11M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $235.77M 10-K · filed 2015-02-24 | $467.93M derived: sum of 2 quarters · filed 2015-02-24 | $676.19M derived: sum of 3 quarters · filed 2015-02-24 | $872.42M 10-K · filed 2016-02-23 | ||
| 2013-09-30 | $232.16M 10-K · filed 2015-02-24 | $440.41M derived: sum of 2 quarters · filed 2015-02-24 | $636.65M 10-Q · filed 2014-11-04 | $820.35M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-06-30 | $208.25M 10-K · filed 2015-02-24 | $404.49M 10-Q · filed 2014-08-05 | $588.19M derived: sum of 3 quarters · filed 2015-02-24 | $763.71M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-03-31 | $196.24M 10-K · filed 2015-02-24 | $379.94M derived: sum of 2 quarters · filed 2015-02-24 | $555.46M derived: sum of 3 quarters · filed 2015-02-24 | $679.69M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2012-12-31 | $183.70M 10-K · filed 2014-02-25 | $359.22M derived: sum of 2 quarters · filed 2014-02-25 | $483.45M derived: sum of 3 quarters · filed 2014-02-25 | $585.98M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | $175.51M 10-K · filed 2014-02-25 | $299.75M derived: sum of 2 quarters · filed 2014-02-25 | $402.28M 10-Q · filed 2013-11-05 | $485.81M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | $124.23M 10-K · filed 2014-02-25 | $129.54M 10-Q · filed 2012-08-07 | $226.76M 10-Q · filed 2013-08-06 | $237.95M 10-Q · filed 2012-08-07 | $310.30M derived: sum of 3 quarters · filed 2014-02-25 | $383.59M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $102.53M 10-K · filed 2014-02-25 | $108.41M 10-Q · filed 2012-05-08 | $186.07M derived: sum of 2 quarters · filed 2014-02-25 | $259.36M derived: sum of 3 quarters · filed 2014-02-25 | $323.93M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $83.54M 10-K · filed 2012-02-28 | $156.83M derived: sum of 2 quarters · filed 2012-11-09 | $221.40M derived: sum of 3 quarters · filed 2012-11-09 | $272.28M 10-K · filed 2014-02-25 | ||
| 2011-09-30 | $73.29M 10-Q · filed 2012-11-09 | $137.86M derived: sum of 2 quarters · filed 2012-11-09 | $188.74M 10-Q · filed 2012-11-09 | $272.28M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-06-30 | $64.57M 10-Q · filed 2012-08-07 | $115.45M 10-Q · filed 2012-08-07 | $198.98M derived: sum of 3 quarters · filed 2013-02-26 | $272.28M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-03-31 | $50.88M 10-Q · filed 2012-05-08 | $134.42M derived: sum of 2 quarters · filed 2013-02-26 | $207.71M derived: sum of 3 quarters · filed 2013-02-26 | $272.28M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2010-12-31 | $83.54M 10-K · filed 2013-02-26 | $53.37M 10-K · filed 2012-02-28 | $156.83M derived: sum of 2 quarters · filed 2013-02-26 | $221.40M derived: sum of 3 quarters · filed 2013-02-26 | $173.78M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $73.29M 10-K · filed 2013-02-26 | $44.75M 10-Q · filed 2011-11-08 | $137.86M derived: sum of 2 quarters · filed 2013-02-26 | $120.41M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $64.57M 10-K · filed 2013-02-26 | $40.49M 10-Q · filed 2011-08-03 | $75.66M 10-Q · filed 2011-08-03 | |||
| 2010-03-31 | $50.88M 10-K · filed 2013-02-26 | $35.17M 10-K · filed 2012-02-28 | ||||
| 2009-12-31 | $128.45M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |